KRAS G12-mutant NSCLC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (NCT03114319) | Novartis Pharmaceuticals | 2017-05-26 |
Track KRAS G12-mutant NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.